The company will showcase translational research using patient-derived models and integrated molecular data across multiple cancer types and therapeutic modalities at the American Association for Cancer Research Annual Meeting in San Diego this April.
Champions Oncology has announced it will present new findings from eight studies at the American Association for Cancer Research Annual Meeting 2026, taking place from 17 to 22 April in San Diego.
The company, a global leader in clinically relevant oncology research models and translational solutions, said the data will span several key areas of cancer drug development, highlighting advances that could help improve decision-making earlier in the research pipeline.
Wide-ranging focus across cancer types and therapies
The presentations will cover a broad range of oncology fields, including KRAS-mutant tumours, ovarian cancer and glioblastoma. Additional research will examine emerging treatment approaches such as radiopharmaceuticals, antibody-drug conjugates and CAR-T therapies.
The presentations will cover a broad range of oncology fields, including KRAS-mutant tumours, ovarian cancer and glioblastoma
Together, the studies aim to demonstrate how researchers and biopharmaceutical companies can better understand how patients respond to treatments, why resistance happens and how to identify biomarkers that can guide more effective therapies.
Champions Oncology said the findings showcase its focus on supporting partners in making more informed development decisions at earlier stages, potentially reducing the risk of failure later in clinical trials.
Improving prediction and reducing risk
The research uses patient-derived models combined with integrated molecular, functional and phenotypic data which allows scientists to more accurately reflect real-world tumour biology in preclinical studies.
By strengthening the link between laboratory research and clinical strategy, these methods are designed to improve prediction of treatment outcomes and reduce uncertainty in drug development.
The company believes that such translational approaches can play a key role in accelerating the development of new cancer therapies, while also improving their chances of success once they reach patients.
Addressing a major challenge in oncology R&D
“At AACR 2026, we are presenting data that directly address one of the biggest challenges in oncology R&D, making better decisions earlier,” said Rob Brainin, Chief Executive Officer of Champions Oncology. “By combining clinically relevant models with deep molecular and functional data, we can help our partners understand response, anticipate resistance and move forward with greater confidence.”
At AACR 2026, we are presenting data that directly address one of the biggest challenges in oncology R&D, making better decisions earlier
The company said its scientists will be available throughout the conference to discuss study design, analytical methods and potential collaboration opportunities with industry partners and researchers.
Topics
- AACR 2026
- Biomarkers
- Cancer
- Cancer research
- Champions Oncology
- Disease Research
- Drug Development
- Drug Discovery
- Immunotherapy
- KRAS-mutant tumours
- Oncology
- oncology drug development
- Organoids
- patient-derived models
- Precision Medicine
- preclinical studies
- translational research
- Translational Science
- treatment resistance
No comments yet